BIVI - IMPORTANT ANNOUNCEMENT: Deadline for BioVie Class Action Lawsuit; Contact Johnson Fistel to Secure Your Rights Now | Benzinga
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP notifies investors of BioVie Inc. ("BioVie" or the "Company") (NASDAQ:BIVI) that a securities class action lawsuit has been filed.
Click Here to Provide Your Information
The BioVie class action lawsuit alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the ongoing COVID-19 pandemic caused "limited access" to clinical trial sites, significantly affecting the Company's ability to conduct proper oversight of the clinical trial; (2) due to the "limited access" to the clinical trial sites, the trial was at higher risk of having "significant deviation from protocol and Good Clinical Practice (GCP) violations" and "anomalous data;" (3) the Company was experiencing issues with the contract research organizations it had retained, creating greater risk of the trial being in non-compliance with GCPs; ...